X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (887) 887
Publication (112) 112
Book Review (15) 15
Book Chapter (12) 12
Conference Proceeding (7) 7
Book / eBook (3) 3
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (783) 783
index medicus (521) 521
uveal melanoma (482) 482
melanoma (434) 434
oncology (372) 372
female (365) 365
male (344) 344
melanoma - pathology (305) 305
uveal neoplasms - pathology (304) 304
melanoma - drug therapy (303) 303
middle aged (285) 285
aged (261) 261
cancer (254) 254
uveal neoplasms - drug therapy (251) 251
ophthalmology (248) 248
adult (245) 245
metastasis (235) 235
melanoma - genetics (193) 193
animals (173) 173
tumors (143) 143
cell line, tumor (142) 142
ocular melanoma (134) 134
prognosis (134) 134
melanoma - secondary (132) 132
uveal neoplasms - genetics (131) 131
care and treatment (129) 129
aged, 80 and over (128) 128
choroidal melanoma (128) 128
melanoma - metabolism (124) 124
treatment outcome (123) 123
liver neoplasms - secondary (122) 122
survival (121) 121
chemotherapy (115) 115
expression (115) 115
malignant-melanoma (110) 110
mutation (109) 109
antineoplastic agents - therapeutic use (102) 102
melanoma - therapy (97) 97
uveal neoplasms - metabolism (96) 96
mice (90) 90
analysis (81) 81
apoptosis (79) 79
therapy (76) 76
mutations (75) 75
skin neoplasms - pathology (75) 75
metastases (73) 73
research (73) 73
article (72) 72
dermatology (72) 72
retrospective studies (70) 70
uveal neoplasms - therapy (69) 69
liver neoplasms - drug therapy (68) 68
neoplasm metastasis (68) 68
gene expression (66) 66
melanoma - mortality (66) 66
skin neoplasms - drug therapy (66) 66
melanoma - radiotherapy (63) 63
antineoplastic combined chemotherapy protocols - therapeutic use (62) 62
proteins (61) 61
liver (60) 60
survival rate (60) 60
antineoplastic agents - pharmacology (59) 59
patients (59) 59
cutaneous melanoma (58) 58
health aspects (58) 58
liver metastases (58) 58
skin neoplasms - genetics (58) 58
medicine, research & experimental (57) 57
cell biology (56) 56
radiotherapy (56) 56
genetic aspects (55) 55
medicine & public health (55) 55
drug therapy (54) 54
follow-up studies (54) 54
medical prognosis (53) 53
metastatic melanoma (53) 53
cell proliferation - drug effects (51) 51
development and progression (51) 51
immunotherapy (51) 51
pathology (50) 50
uveal neoplasms - mortality (50) 50
angiogenesis (49) 49
cells (49) 49
eye diseases (49) 49
surgery (49) 49
tumor cells, cultured (49) 49
cancer therapies (48) 48
immunohistochemistry (48) 48
uveal neoplasms - radiotherapy (48) 48
medicine (47) 47
eye (45) 45
kinases (45) 45
survival analysis (44) 44
melanoma - diagnosis (43) 43
risk factors (43) 43
activation (42) 42
cancer research (42) 42
cell proliferation (42) 42
growth (42) 42
neoplasm staging (42) 42
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (874) 874
French (7) 7
German (5) 5
Japanese (2) 2
Portuguese (2) 2
Russian (2) 2
Hebrew (1) 1
Hungarian (1) 1
Italian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 8, pp. 782 - 789
Summary Background MEK is a member of the MAPK signalling cascade that is commonly activated in melanoma. Direct inhibition of MEK blocks cell proliferation... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | BRAF | ONCOLOGY | RAF | SOMATIC MUTATIONS | PROGRESSION | Skin Neoplasms - drug therapy | United States | Humans | Middle Aged | Melanoma - enzymology | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Uveal Neoplasms - enzymology | Young Adult | Pyridones - administration & dosage | Skin Neoplasms - enzymology | Time Factors | Antineoplastic Agents - adverse effects | DNA Mutational Analysis | Melanoma - genetics | Skin Neoplasms - mortality | Adult | Female | Skin Neoplasms - pathology | MAP Kinase Kinase 1 - antagonists & inhibitors | Uveal Neoplasms - genetics | Uveal Neoplasms - pathology | Drug Administration Schedule | Administration, Oral | Pyrimidinones - adverse effects | Kaplan-Meier Estimate | MAP Kinase Kinase 1 - metabolism | Treatment Outcome | MAP Kinase Kinase 2 - metabolism | Melanoma - pathology | Uveal Neoplasms - drug therapy | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | MAP Kinase Kinase 2 - antagonists & inhibitors | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Uveal Neoplasms - mortality | Aged | Pyrimidinones - administration & dosage | Mutation | Pyridones - adverse effects | Melanoma - mortality | Prevention | Care and treatment | Melanoma | Cancer | Index Medicus
Journal Article
Cancer, ISSN 0008-543X, 11/2016, Volume 122, Issue 21, pp. 3354 - 3362
Journal Article
Journal Article
Cancer, ISSN 0008-543X, 11/2016, Volume 122, Issue 21, pp. 3344 - 3353
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2016, Volume 96, Issue 4, pp. 808 - 819
Abstract Purpose /Objective(s): To report clinical outcomes of head and neck reirradiation with proton therapy. Methods and Materials Between 2004–2014, 61... 
Radiology | Hematology, Oncology and Palliative Medicine | SALVAGE REIRRADIATION | CETUXIMAB | MANAGEMENT | PROGNOSTIC-FACTORS | UVEAL MELANOMA | ONCOLOGY | SQUAMOUS-CELL CARCINOMA | PERINEURAL SPREAD | RADIOTHERAPY | RADIATION | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | CHEMOTHERAPY | Neoplasm Recurrence, Local - radiotherapy | Follow-Up Studies | Skin Neoplasms - radiotherapy | Carcinoma, Squamous Cell - pathology | Humans | Middle Aged | Salvage Therapy | Male | Neoplasms, Second Primary - mortality | Carcinoma, Squamous Cell - radiotherapy | Neoplasm Recurrence, Local - mortality | Neoplasms, Second Primary - radiotherapy | Neoplasm, Residual | Carcinoma, Squamous Cell - mortality | Karnofsky Performance Status | Time Factors | Aged, 80 and over | Adult | Female | Radiotherapy Dosage | Carcinoma, Adenoid Cystic - pathology | Re-Irradiation - adverse effects | Head and Neck Neoplasms - drug therapy | Kaplan-Meier Estimate | Treatment Outcome | Head and Neck Neoplasms - pathology | Head and Neck Neoplasms - radiotherapy | Carcinoma, Adenoid Cystic - mortality | Carcinoma, Squamous Cell - drug therapy | Proton Therapy | Aged | Carcinoma, Adenoid Cystic - radiotherapy | Head and Neck Neoplasms - mortality | Relative Biological Effectiveness | Yuan (China) | Medical colleges | Care and treatment | Health aspects | Radiation | Cancer | Index Medicus | HEAD | PATIENTS | NEOPLASMS | RADIOLOGY AND NUCLEAR MEDICINE | PROTON BEAMS | DEATH | RADIATION DOSES | NECK | GY RANGE 10-100
Journal Article
Annals of Surgical Oncology, ISSN 1068-9265, 4/2016, Volume 23, Issue 4, pp. 1309 - 1319
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2016, Volume 34, Issue 29, pp. 3562 - 3569
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 03/2015, Volume 10, Issue 3, pp. e0118564 - e0118564
Journal Article